CCO Oncology Podcast artwork

PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

CCO Oncology Podcast

English - October 26, 2021 20:30 - 19 minutes - 18.2 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
Next Episode: Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

Importance of germline and somatic testingAdverse events associated with PARP inhibitorsMaintenance therapy in pancreatic cancer

Presenters:

Philip Agop Philip, MD, PhD, FRCP
Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Elena Gabriela Chiorean, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program:
https://bit.ly/3jEehCc

Link to associated downloadable PDF:
https://bit.ly/3nSfTcR